Sweden-based Bonesupport intends to launch an initial public offering on the Swedish stock exchange, Nasdaq Stockholm, in hopes of obtaining $45 million. The company, a maker of drug-eluting bone scaffolds, plans to use the proceeds to support sales expansion in the US and Europe, as well as for completing a US pivotal trial for its Cerament G bone filler and generating clinical and health economics and outcomes research data.
Swedish IPO could bring in $45M for Bonesupport
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.